Results 101 to 110 of about 30,099 (284)

Halogen Bonding in Nucleic Acid Complexes

open access: yes, 2017
Halogen bonding (X-bonding) has attracted notable attention among noncovalent interactions. This highly directional attraction between a halogen atom and an electron donor has been exploited in knowledge-based drug design. A great deal of information has
Kolář, Michal H., Tabarrini, Oriana
core   +1 more source

Will drug resistance against dolutegravir in initial therapy ever occur? [PDF]

open access: yes, 2015
Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir (RAL) and elvitegravir (EVG), DTG shows a limited cross ...
Mark A. Wainberg, Ying-Shan Han
core   +2 more sources

Prevalence of Sleep Apnea and Sleepiness in Adults With and Without HIV in Mwanza, Tanzania: Baseline Results From an Ongoing Cohort Study

open access: yesJournal of Sleep Research, EarlyView.
ABSTRACT We conducted a cross‐sectional analysis of the baseline survey of participants aged > 30 years enrolled in the Mwanza HIV&CVD Cohort in Tanzania. Our primary objective was to examine the association between HIV status and sleep apnea (SA).
Godfrey A. Kisigo   +9 more
wiley   +1 more source

Comparative replication capacity of raltegravir-resistant strains and antiviral activity of the new-generation integrase inhibitor dolutegravir in human primary macrophages and lymphocytes [PDF]

open access: yes, 2014
To evaluate the replication capacity and phenotypic susceptibility to dolutegravir and raltegravir of wild-type and raltegravir-resistant HIV-1 strains in several cellular ...
Calvez, V   +11 more
core   +1 more source

Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous–venous extracorporeal membrane oxygenation (VV‐ECMO): A case report

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1487-1492, May 2026.
While providing potentially life‐saving cardiorespiratory support for critically ill patients, extracorporeal membrane oxygenation (ECMO) may detrimentally affect pharmacokinetic (PK) performance and concurrent drug efficacy and safety. We describe a patient with Pneumocystis jirovecii pneumonia (PJP) in the context of acquired immunodeficiency ...
Tom C. Zwart   +7 more
wiley   +1 more source

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?

open access: yesEuropean Journal of Medical Research, 2009
End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined.
Vogel Martin, Nelson Mark
doaj   +1 more source

Reversal of Epigenetic Silencing Allows Robust HIV-1 Replication in the Absence of Integrase Function

open access: yesmBio, 2020
Integration of the proviral DNA intermediate into the host cell genome normally represents an essential step in the retroviral life cycle. While the reason(s) for this requirement remains unclear, it is known that unintegrated proviral DNA is ...
Ishak D. Irwan   +4 more
doaj   +1 more source

Distribution and Redistribution of HIV-1 Nucleocapsid Protein in Immature, Mature, and Integrase-Inhibited Virions: a Role for Integrase in Maturation [PDF]

open access: yes, 2015
During virion maturation, HIV-1 capsid protein assembles into a conical core containing the viral ribonucleoprotein (vRNP) complex, thought to be composed mainly of the viral RNA and nucleocapsid protein (NC).
Cheng, N   +7 more
core   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1136-1140, May 2026.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1179-1194, May 2026.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy